Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 139.93M | 89.08M | 49.01M | 22.59M | 14.68M |
Gross Profit | 98.94M | 53.77M | 21.33M | 4.52M | 1.71M |
EBITDA | -23.76M | -41.04M | -57.78M | -41.01M | 32.15M |
Net Income | -27.45M | -48.61M | -66.76M | -48.69M | 27.57M |
Balance Sheet | |||||
Total Assets | 318.56M | 182.55M | 150.16M | 192.72M | 100.68M |
Cash, Cash Equivalents and Short-Term Investments | 237.22M | 127.18M | 105.80M | 159.33M | 68.97M |
Total Debt | 12.30M | 3.01M | 44.99M | 44.93M | 30.75M |
Total Liabilities | 37.33M | 22.19M | 60.26M | 54.48M | 398.21M |
Stockholders Equity | 281.24M | 160.36M | 89.90M | 138.24M | -297.53M |
Cash Flow | |||||
Free Cash Flow | -22.39M | -46.41M | -61.24M | -46.65M | -37.74M |
Operating Cash Flow | -16.95M | -41.59M | -58.85M | -44.71M | -35.20M |
Investing Cash Flow | -99.31M | -22.13M | 39.95M | -81.91M | 15.59M |
Financing Cash Flow | 123.32M | 61.52M | 6.33M | 137.34M | 25.24M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $596.17M | ― | -7.22% | ― | 18.81% | 67.41% | |
61 Neutral | $759.39M | ― | -15.96% | ― | 22.60% | 41.26% | |
55 Neutral | $432.56M | ― | -27.82% | ― | 5.85% | -8.92% | |
51 Neutral | $7.30B | 0.27 | -62.71% | 2.44% | 15.02% | 0.60% | |
51 Neutral | $535.58M | ― | -19.79% | ― | 8.60% | -42.76% | |
48 Neutral | $520.46M | ― | 26.25% | ― | ― | ― | |
45 Neutral | $318.19M | ― | -11.98% | ― | 46.69% | 46.68% |
RxSight held its 2025 Annual Meeting of Stockholders on June 3, 2025, where approximately 79.2% of the outstanding shares were represented. During the meeting, three Class I directors, Ron Kurtz, M.D., J. Andy Corley, and Juliet Tammenoms Bakker, were re-elected to serve until the 2028 annual meeting. Additionally, the stockholders approved the executive compensation and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (RXST) stock is a Buy with a $73.00 price target. To see the full list of analyst forecasts on RxSight stock, see the RXST Stock Forecast page.